AG2304 vs Atozet (ezetimibe/atorvastatin)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: HMG-CoA reductase / NPC1L1 · full Atherosclerotic Cardiovascular Disease pipeline
AG2304
Developed by Ahn-Gook Pharmaceutical
NCT06717360 · Phase 3 · completed
The study randomly assigned 158 participants and used quadruple masking with AG2304R as an active comparator. Its primary endpoint was LDL-C, a surrogate biomarker, and the outcome comparison cannot yet be assessed because results are not posted.
No aligned efficacy figure on record for this race.
Atozet (ezetimibe/atorvastatin)
Rights held by Organon and partners; US product discontinued
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | AG2304 | Atozet (ezetimibe/atorvastatin) |
|---|---|---|
| LDL-C, % change | —Not posted · NCT06717360 | -49.0% vs -27.8%vs AtorvastatinNCT057614441 other result
|
| Non-HDL-C, % change | —Not posted · NCT06717360 | —Not reported |
| ApoB, % change | —Not posted · NCT06717360 | —Not reported |
| Lp(a), % change | —Not posted · NCT06717360 | —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT06717360 | —Not reported |
LDL-C, % change
- AG2304
- —Not posted · NCT06717360
- Atozet (ezetimibe/atorvastatin)
- -49.0% vs -27.8%vs AtorvastatinNCT05761444
1 other result
- -50.4% vs -34.4% NCT05761444
Non-HDL-C, % change
- AG2304
- —Not posted · NCT06717360
- Atozet (ezetimibe/atorvastatin)
- —Not reported
ApoB, % change
- AG2304
- —Not posted · NCT06717360
- Atozet (ezetimibe/atorvastatin)
- —Not reported
Lp(a), % change
- AG2304
- —Not posted · NCT06717360
- Atozet (ezetimibe/atorvastatin)
- —Not reported
3-point MACE (% with event)
- AG2304
- —Not posted · NCT06717360
- Atozet (ezetimibe/atorvastatin)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
AG2304: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. AG2304: 0 of 4 rows · Atozet (ezetimibe/atorvastatin): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Atozet (ezetimibe/atorvastatin) |
|---|---|
| Dropout rate | 11.9% NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4 |
| Discontinued due to AEs | 3% NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4 |
| Serious AEs | 6% NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4 |
| Most frequent reported AEs | alanine aminotransferase increased 1.5% alopecia 1.5% anaemia 1.5% NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Atozet (ezetimibe/atorvastatin)
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AG2304's landscape · Atozet (ezetimibe/atorvastatin)'s landscape